Skip Ribbon Commands
Skip to main content
Menu

Theranostic Study

Neuroendocrine Tumors

Neuroendocrine tumours are rare tumours that develop from neuroendocrine cells. These cells have the traits of hormone-producing cells and nerve cells. They are found all over the body. Symptoms depend on the site and the type of neuroendocrine tumour. Most neuroendocrine tumours have somatostatin receptors which can be detected on the Ga68-dotapeptide scan. Patients with advanced and non-operable neuroendocrine tumours that show uptake on the dotapeptide scans can be treated with Lu-177 Dotatate therapy or peptide receptor radionuclide therapy (PRRT). Our department was one of the first in the region to offer this treatment option and our experience dates back to 2012. Our research activities include the long term follow up of our patients to evaluate the outcomes and improve patient selection. We are also involved in trials in collaboration with our radiation and medical oncologists looking at the use of dotapeptide scans and therapy in other somatostatin positive tumours such as nasopharyngeal carcinoma.


Contact: 
Please contact Dr Tham Wei Ying, email: tham.wei.ying@singhealth.com.sg for more information.

Publications:
  1. Low HC, Tay YS, Ong SYK, Tham WY, Yan SX. Peptide Receptor Radionuclide Therapy Performed Shortly after administration of Long-Acting Octreotide. Clin Nucl Med 2023; 48(12): 1086-1088. Available from DOI: 10.1097/RLU.0000000000004906.
  2. Low HC, Loke KSH, Wang FQ, Han S, Nei WL. 68Ga-DOTATATE PET/CT of Metastatic Lymphoepithelial Carcinoma of Parotid Gland. Clin Nucl Med 2023; 48(12): 1056-1058. Available from DOI: 10.1097/RLU.0000000000004899.
  3. Koo SX, AK Tong, SY Soh, M Farid, A Loh, KS Loke. Selective use of Peptide Receptor Radionuclide Therapy following comparative imaging of Ga-68 DOTATATE PET/CT against I-131 MIBG scintigraphy in a small Asian cohort of Adult neuroblastoma. Med J Malaysia 2021; 76(4):573-577.
  4. Tang CYL, Chua WM, Huang HL, Lam WWC, Loh LM, Tai D, Ong SYK, Yan SX, Loke KSH, Ng DCE, Tham WY. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. J Neuroendocrinol. 2023;e13349. doi:10.1111/jne.13349

Hepatocellular Cancer & Liver Metastases

Liver cancer is the 5th most common cancer in men in Singapore in the years 2017-2021, with more than 2,900 cases reported in these 5 years. There have been significant advances in the diagnosis and treatment of these tumours in the last 2 decades, but many aspects are still unknown, especially relating to the genomic-metabolomic-biologic intercorrelations and tumour heterogeneity. The department has been involved in research in liver cancer (hepatocellular carcinomas and cholangiocarcinomas), in conjunction with liver surgeons, gastroenterologists, interventional radiologists, radiation oncologists, medical oncologists, pathologists and the research eco-system of SINGHEALTH-DUKE NUS. Research areas include data analytics on overall survival, progression free survivals, Y90-PET imaging, partition-modelling, voxel dosimetry and biological tumour response. The department was an early investigator of the cellular effects of Y90 microspheric radiation in tumour immunomodulation, and clinical evaluation of Y90 microspheres with immune checkpoint inhibitors. Multi-sites international trials includes SIRFLOX, SIVERNIB and STRATUM.

Contact:

Please contact Prof David Ng Chee Eng, email: david.ng.c.e@singhealth.com.sg for more information.

Publications:

  1. Goh Anthony Soon-Whatt; Chung Alexander Yaw-Fui; Lo Richard Houa-Gong; Lau Te-Neng; Yu Sidney Wing-Kwong; Chng May; Satchithanantham Somanesan; Loong Susan Li-Er; Ng David Chee-Eng; Lim Beng-Choo; Connor Stephen; Chow Pierce Kah-Hoe. A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. International Journal of Radiation Oncology, Biology, Physics 2007; 67(3):786-792.
  2. Kao Yung Hsiang; Hock Tan Andrew Eik; Burgmans Mark Christiaan; Irani Farah Gillian; Khoo Li Ser; Gong Lo Richard Hoau; Tay Kiang Hiong; Tan Bien Soo; Hoe Chow Pierce Kah; Eng Ng David Chee; Whatt Goh Anthony Soon. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. Journal of Nuclear Medicine 2012; 53(4):559-566.
  3. Andrew Yu-Keat Khor, Ying Toh, John Carson Allen, David Chee-Eng Ng, Yung-Hsiang Kao, Guili Zhu, Su-Pin Choo, Richard Hoau-Gong Lo, Kiang-Hiong Tay, Jin-Yao Teo, Brian Kim-Poh Goh, Mark Christiaan Burgmans, Farah Gillian Irani, Anthony Soon-Whatt Goh, Pierce Kah-Hoe Chow. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatology International 2014; 8:395-404.
  4. Pierce KH Chow, Richard HG Lo, David WM Tai, Kiang Hiong Tay, Kelvin SH Loke, Chow Wei Too, Kiat Hon Lim, Su Pin Choo, Michael LC Wang, Brian KP Goh, Anthony SW Goh, Sue Ping Thang, Farah Gillian Irani, Choon Hua Thng, David CE Ng, Han Chong Toh, Jen San Wong, Sean X Yan, Apoorva Gogna, Sum Leong. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer 2016; 5(2):97-106.
  5. Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, Chung A, Lo RHG, Ng D, Filarca RLF, Albani S, Chow PKH. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019; 68: 335-346.
  6. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB : Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncology 2018; 36(19):1913-1921.
  7. Tong Aaron KT; Kao Yung Hsiang; Too Chow Wei; Chin Kenneth FW; Ng David CE; Chow Pierce KH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. British J Radiology 2016; 89: 43.

Prostate Cancer

In Singapore, prostate cancer is the most frequent incident cancer diagnosed and 5th most common cause of cancer-related deaths in men from 2017 to 2021. Over the last decade, Nuclear Medicine involvement in the management of prostate cancer is primarily related to the high accuracy of prostate-specific membrane antigen (PSMA) PET/CT scan for detection of prostate cancer, and individualized treatment with PSMA-targeted radioligand therapy for prostate cancer with high PSMA expression. Our research activities include analyzing and publishing our clinical experience, as well as involvement in multisite international trials such as AMG 160, PSMAddition, and upcoming PSMA Care and OMPC. Notably, we have also been involved in the international studies (ALSYMPCA and ERA 223 using Radium-223 dichloride in prostate cancer patients with symptomatic bone metastases.

Contact:
Please contact Asst Prof Thang Sue Ping, email: thang.s.p@singhealth.com.sg for more information.

Publications:

  1. 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Tan JSH, Goh CXY, Koh YS, Li Y, Tuan JKL, Chua ET, Tan TWK, Wang MLC, Lee LS, Tay KJ, Kanesvaran R, Toh CK, Tong AKT, Lam WWC, Chua MLK. Cancer Biol Med. 2019 Feb;16(1):157-166. doi: 10.20892/j.issn.2095-3941.2018.0288.
  2. Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population. Thang SP, Lam WWC, Tong AKT, Allen JC Jr, Ler ASL, Tay YS, Somanesan S, Kanesvaran R, Wong ASC, Ng DCE.Nucl Med Commun. 2020 Jul;41(7):618-628. doi: 10.1097/MNM.0000000000001179.
  3. Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study). Chua WM, Lam WW, Tong AK, Sultana R, Kua SMY, Kanesvaran R, Wong ASC, Tay KJ, Cheng TJL, Ng DCE, Thang SP. Asia Pac J Clin Oncol. 2023 Mar 31. doi: 10.1111/ajco.13944.
  4. Optimization of Bayesian penalized likelihood reconstruction for 68 Ga-prostate-specific membrane antigen-11 PET/computed tomography. Tang CYL, Lim GKY, Chua WM, Ng CWQ, Koo SX, Goh CX, Thang SP, Zaheer S, Lam WWC, Huang HL.Nucl Med Commun. 2023 Jun 1;44(6):480-487. doi: 10.1097/MNM.0000000000001687.
  5. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K. Eur Urol. 2023 Jul;84(1):36-48. doi: 10.1016/j.eururo.2023.03.001

Thyroid Cancer

Differentiated thyroid cancer is the 2nd most common cancer diagnosed in Singaporean women below the age of 40 years and overall, the 8th most common cancer in women. The incidence of thyroid cancer has been steadily increasing globally. Nuclear Medicine plays a unique role in the diagnosis and treatment of patients with thyroid cancer.  Our department, together with our surgical and endocrinology collaborators, has been actively researching on improving care and novel treatments for thyroid cancer patients such as the study of radiation dosimetry using I-124 and redifferentiation therapy with MEK and BRAF inhibitors.



Successful redifferentiation of iodine-refractory disease with subsequent I-131 treatment and interval partial response

Contact:
Please contact A/Prof Kelvin Loke, email: kelvin.loke.s.h@singhealth.com.sg for more information.

Publications:

  1. Zaheer S, Tan A, Ang ES, Loke KS, Kao YH, Goh A, Wong WY. Post-thyroidectomy neck ultrasonography in patients with thyroid cancer and a review of the literature. Singapore Med J. 2014 Apr;55(4):177-82,; quiz 183. doi: 10.11622/smedj.2014050. PMID: 24763832; PMCID: PMC4291944.
  2. Kao YH, Gan HK, Zaheer S, Lam WW, Loke KS, Wong WY, Ng DC, Goh AS. Gender, Race, and Age at Diagnosis as Risk Factors for Metastasis or Recurrence among 1,657 Thyroid Cancer Patients Treated with Radioiodine across 40 Years in Singapore. Oncol Res Treat. 2015;38(12):679-82. doi: 10.1159/000442114. Epub 2015 Nov 18. PMID: 26633801. 
  3. Tang CYL, Thang SP, Zaheer S, Kwan CK, Ng DC. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population. Endocrine. 2020 Jul;69(1):126-132. doi: 10.1007/s12020-020-02238-z. Epub 2020 Feb 28. PMID: 32112240. 
  4. Sek KS, Tsang I, Lee XY, Albaqmi OH, Morosan Allo YJ, Rosmarin MC, Mahrous AK, Parameswaran R, Ng DCE, Tong AKT, Loke KSH, Brenta G, Alghamdi AH, Albati NA, Fish SA, Tuttle RM, Yang SP. Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. Clin Endocrinol (Oxf). 2021 Mar;94(3):504-512. doi: 10.1111/cen.14325. Epub 2020 Sep 26. PMID: 32886805. 
  5. Yang SP, Koh LCW, Kong KW, Parameswaran R, Loke KSH, Ngiam KY, Tan WB, Loh T, Ng DCE, Goh BC, Ngeow J, Tai ES. A Multiplex Thyroid-Specific Assay for Quantification of Circulating Thyroid Cell-Free RNA in Plasma of Thyroid Cancer Patients. Front Genet. 2021 Aug 25;12:721832. doi: 10.3389/fgene.2021.721832. PMID: 34512731; PMCID: PMC8425593.
  6. Huang, H. L., Loke, S. H., Zaheer, S., & Ng, C. E. (2022). Adjuvant Treatment and Follow-Up Of Thyroid Cancers. Mishra, A.K., Agarwal, A., Parameswaran, R., & Singh, K.R. (Eds.). Endocrine Surgery: A South Asian Perspective (1st ed.) (Pages 204-210). CRC Press. https://doi.org/10.1201/9780429197338

Other Cancers

The Department of Nuclear Medicine and Molecular Imaging strives to be at the forefront of nuclear theranostics, to research and discover new radiopharmaceuticals which might become clinically relevant. This often involves the discovery of novel compounds or discovering new ways to treat existing diseases. We are currently collaborating with medical and radiation oncologists to treat nasopharyngeal carcinoma with peptide receptor radionuclide therapy.

Contact:
Please contact A/Prof Kelvin Loke, email: kelvin.loke.s.h@singhealth.com.sg for more information.


Correlation between DOTATATE and FDG uptake with EBER staining on histology 

Publications:

  1. Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, Pipinikas CP, Chung GT, Chan YY, Wu F, To KF, Tsang CM, Pearce W, Morelli D, Philpott M, Masterson L, Nibhani R, Wells G, Bell CG, Koller J, Delecluse S, Yip YL, Liu J, Forde CT, Forster MD, Jay A, Dudás J, Krapp A, Wan S, Uprimny C, Sprung S, Haybaeck J, Fenton TR, Chester K, Thirlwell C, Royle G, Marafioti T, Gupta R, Indrasari SR, Herdini C, Slim MAM, Indrawati I, Sutton L, Fles R, Tan B, Yeong J, Jain A, Han S, Wang H, Loke KSH, He W, Xu R, Jin H, Cheng Z, Howard D, Hwang PH, Le QT, Tay JK, West RB, Tsao SW, Meyer T, Riechelmann H, Oppermann U, Delecluse HJ, Willems SM, Chua MLK, Busson P, Lo KW, Wollmann G, Pillay N, Vanhaesebroeck B, Lund VJ. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021 Jan 5;12(1):117. doi: 10.1038/s41467-020-20308-8. PMID: 33402692; PMCID: PMC7785735.
  2. Kumaran A, Koo SX, Yeong J, Takano AM, Farid M, Loke SH, Nei WL. Imaging and treatment with 68Gallium and 177Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung. BJR Case Rep. 2022 Nov 8;9(1):20220094. doi: 10.1259/bjrcr.20220094. PMID: 36873236; PMCID: PMC9976727.
  3. Nei WL, Jain A, Wang FQ, Khor LK, Yeong JP, Han ST, Sommat K, Ang MK, Soong YL, Loke KSH. Somatostatin receptor imaging in nasopharyngeal cancer. Ann Nasopharynx Cancer 2018;2:2. doi: 10.21037/anpc.2018.01.01